Brokerages expect Anavex Life Sciences (NASDAQ:AVXL) to report earnings of ($0.10) per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Anavex Life Sciences’ earnings. Anavex Life Sciences posted earnings of ($0.09) per share in the same quarter last year, which would indicate a negative year over year growth rate of 11.1%. The firm is expected to issue its next quarterly earnings results on Wednesday, May 9th.
On average, analysts expect that Anavex Life Sciences will report full year earnings of ($0.41) per share for the current fiscal year, with EPS estimates ranging from ($0.42) to ($0.40). For the next year, analysts expect that the company will report earnings of ($0.48) per share. Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side analysts that cover Anavex Life Sciences.
Anavex Life Sciences (NASDAQ:AVXL) last posted its quarterly earnings data on Wednesday, February 7th. The biotechnology company reported ($0.09) earnings per share for the quarter.
Several analysts have recently weighed in on the stock. Roth Capital began coverage on shares of Anavex Life Sciences in a research report on Thursday, March 8th. They set a “buy” rating and a $6.00 price objective on the stock. Zacks Investment Research raised shares of Anavex Life Sciences from a “hold” rating to a “buy” rating and set a $3.00 target price on the stock in a report on Thursday, March 22nd. Maxim Group set a $5.00 target price on shares of Anavex Life Sciences and gave the company a “buy” rating in a report on Thursday, February 8th. Finally, Noble Financial reaffirmed a “buy” rating on shares of Anavex Life Sciences in a report on Wednesday, February 21st. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the company. Anavex Life Sciences currently has an average rating of “Buy” and a consensus target price of $7.19.
Shares of Anavex Life Sciences stock traded up $0.02 on Tuesday, hitting $2.28. 226,030 shares of the company traded hands, compared to its average volume of 317,258. The stock has a market cap of $101.63, a P/E ratio of -6.91 and a beta of 0.88. Anavex Life Sciences has a 12-month low of $1.85 and a 12-month high of $6.27.
Several hedge funds have recently added to or reduced their stakes in AVXL. Millennium Management LLC grew its holdings in Anavex Life Sciences by 95.2% in the 4th quarter. Millennium Management LLC now owns 44,895 shares of the biotechnology company’s stock worth $145,000 after acquiring an additional 21,895 shares during the last quarter. The Manufacturers Life Insurance Company boosted its stake in shares of Anavex Life Sciences by 37.7% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 31,876 shares of the biotechnology company’s stock valued at $169,000 after purchasing an additional 8,728 shares in the last quarter. Wells Fargo & Company MN boosted its stake in shares of Anavex Life Sciences by 40.8% during the 3rd quarter. Wells Fargo & Company MN now owns 56,873 shares of the biotechnology company’s stock valued at $236,000 after purchasing an additional 16,488 shares in the last quarter. Deutsche Bank AG boosted its stake in shares of Anavex Life Sciences by 150.9% during the 4th quarter. Deutsche Bank AG now owns 82,967 shares of the biotechnology company’s stock valued at $266,000 after purchasing an additional 49,904 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its stake in shares of Anavex Life Sciences by 60.3% during the 4th quarter. Bank of New York Mellon Corp now owns 177,938 shares of the biotechnology company’s stock valued at $573,000 after purchasing an additional 66,931 shares in the last quarter. 22.75% of the stock is currently owned by institutional investors.
TRADEMARK VIOLATION WARNING: “Brokerages Expect Anavex Life Sciences (AVXL) to Announce -$0.10 EPS” was originally published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this news story on another site, it was stolen and republished in violation of US and international copyright & trademark laws. The correct version of this news story can be viewed at https://ledgergazette.com/2018/04/22/brokerages-expect-anavex-life-sciences-avxl-to-announce-0-10-eps.html.
Anavex Life Sciences Company Profile
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of Alzheimer's disease, other central nervous system diseases, pain, and various cancers. The company's lead drug candidates include ANAVEX 2-73, which has completed Phase IIa clinical trials for the treatment of Alzheimer's disease; and in preclinical clinical trials to treat Parkinson's disease, epilepsy, Rett syndrome, Angelman syndrome, multiple sclerosis, and Fragile X syndrome.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Anavex Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.